Draft. Pending scientific and legal review. Not medical advice.
Multi-omics: transcriptomics, epigenetics, proteomics and metabolomics
Multi-omics extends genomics with layers of gene expression, epigenetic regulation, proteins and metabolites. In the catalogue, transcriptomics and epigenetics (methylome) are available by clinical area; proteomics and metabolomics are listed as coming soon. They do not replace the clinical phenotype.
Available layers
According to the catalogue and the site multiomic reading:
- Transcriptomics: gene expression oriented to available clinical areas. - Epigenetics / methylome: methylation patterns and regulation without changing the DNA sequence. - Proteomics: presence, abundance and modifications of proteins (coming soon in the catalogue). - Metabolomics: metabolite profiling (coming soon).
These layers are offered by clinical axes (for example neurology, oncology and cardiology) when the sheet indicates so. The microbiome is described in its own catalogue service line and is not detailed here as a product.
Clinical areas covered today
For transcriptomics and epigenetics, the catalogue indicates availability along neurology, oncology and cardiology axes, with concrete entities listed per layer (for example Alzheimer disease, Parkinson disease, migraine, several cancers, Brugada syndrome or cardiomyopathies). Proteomics and metabolomics appear as coming soon, without active clinical lists.
This page does not turn each entity into a commercial offer. It names the analysis type and points to the professional catalogue for operational detail.
Integration with phenotype
DNA alone does not provide the full picture. Epigenomics, transcriptomics, proteomics, metabolomics and the microbiome widen the perspective. Integrating them with the clinical phenotype supports a more complete understanding of the patient and more precise prevention and treatment strategies, always under professional judgement.
Epigenetic changes do not necessarily imply disease presence or development. Meaning depends on the modification type, region, tissue and available evidence. Epigenetic marks are dynamic.
Method transparency
The site emphasises explicit methods (NGS, metagenomics and other techniques described per line) and avoids absolute clinical promises. Trust is built with verifiable catalogue information.
Pending Phase 0: turnaround, samples and sensitivity per layer; real availability dates for proteomics and metabolomics.
